Background. To elucidate the regulation of peroxisome proliferator-activated receptor c (PPARc) and its roles in mesangial cells, we examined the expression of PPARc1 and effects of its ligands on cell phenotypes and angiotensin IIinduced contractile response in cultured rat mesangial cells under a high (20 mmol/L) glucose condition.
role in regulation of cell differentiation at transcriptional levels [1] [2] [3] . Fibroblasts are reported to differentiate to adipocytes by the activation of PPARc [1] . We also reported the expression of PPARc1 in rat mesangial cells and the function of PPARc1 to regulate the differentiation of the cells by showing changes of a-smooth muscle actin expression [4] . Cell differentiation seems to regulate cell functions by changing the phenotypes of the cells. Phenotypic changes occur in many types of cells under various conditions [5, 6] . In vascular smooth muscle cells, two phenotypes, namely synthetic phenotype and contractile phenotype, are reported, and the former changed from the latter loses contractile function and induces cellular proliferation and protein production such as extracellular matrices [7, 8] .
Glomerular hyperfiltration prior to pathologic changes such as glomerular basement membrane thickening and mesangial expansion seems to be the first change in diabetic nephropathy [9, 10] . With respect to the regulation of glomerular filtration, mesangial cells play an important role by altering their cellular tone [11, 12] . Mesangial cells during long-term high glucose conditions are reported to lose their contractile response to contracting substances such as angiotensin II and endothelin [13, 14] . Recent studies have shown that high glucose concentrations can induce phenotypic changes in mesangial cells [15, 16] . The phenotypic change in mesangial cells is considered to occur in the early stage of diabetes in vivo [16] .
Activation of PPARc by its ligands has been reported to induce beneficial effects on PPARc expressing cells by modulating their phenotype. PPARc ligands inhibit macrophages in atherosclerosis and inflammatory functions of activated monocytes in rheumatoid arthritis, and induce apoptosis in neoplasms such as lung and breast cancer [17] [18] [19] [20] . Thiazolidinediones and 15deoxy-12, 14 delta-prostaglandin J2 (15dPGJ2) are synthesized PPARc ligands and natural PPARc ligand, respectively [21] . Thiazolidinediones have been used as antidiabetic drugs, and were reported to result in amelioration of diabetic nephropathy without affecting blood glucose levels and blood pressure in streptozotocin-induced diabetic rats [22] . Recently, some of prostaglandin-synthesis inhibitors such as indomethacin and fenoprofen are reported to act as PPARc ligands, while acetyl salicylic acid does not [23] .
Based on these observations, it is possible that PPARc1 in mesangial cells may be involved in the contractile dysfunction of the cells under high glucose environment by changing the cellular phenotype through activation of PPARc1. However, whether the expression of PPARc1 actually changes phenotype of the cells under high glucose environment has not yet been determined.
The aim of the present study was done to determine the expression PPARc1 in the presence of high glucose concentrations, and to investigate whether activation of PPARc1 by its ligands attenuates the reduced contractile response of rat mesangial cells under the high glucose condition.
METHODS

Cell preparation
Mesangial cells were isolated from kidneys of fourweek-old Sprague-Dawley rats by the differential sieving procedure reported previously [24] . The cells were cultured in plastic plates (Nunc Brand Products, Roskilde, Denmark) in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F-12 (both from Sigma, St. Louis, MO, USA) containing 10% fetal bovine serum (FBS) (Gibco BRL, Grand Island, NY, USA), 10% Nu-serum (Collaborative Research, Bedford, MA, USA), penicillin (100 U/mL), and streptomycin (100 lg/ mL) (Sigma). Rat mesangial cells at passages 3-5 from five different preparations were used for the following experiments.
Western blots of PPAR c1 and a-smooth muscle actin
Rat mesangial cells on 60 mm plastic plates (Nunc) were cultured with DMEM-F12 containing 10% FBS and 10% Nu-serum with either 5 or 20 mmol/L glucose in the presence or absence of 10 −6 mol/L pioglitazone, 10 −5 mol/L 15dPGJ2, a natural PPARc ligands, 2× 10 −5 mol/L indomethacin 10 −4 mol/L acetyl salicylic acid and 4 × 10 −6 mol/L PD98059, which inhibits the activation of mitogen-activated protein kinase (MAPK) by mitogen-activated protein kinase kinase (MAPKK) [25] , for 5 days. The effect of protein kinase C (PKC) activation with preincubation of 10 −8 mol/L of 12-Otetradecarbonyl 13-acetate (TPA) for 20 minutes and the effect of 10 −11 mol/L tumor necrosis factor a (TNFa) on PPAR c1 protein were also examined in the presence and absence of PD98059 in DMEM-F12 with 5 mmol/L glucose. The medium was changed every day. Western blotting of PPARc1 and a-smooth muscle actin was performed as described previously [4] . Briefly, mesangial cells were harvested and lysed in a solution containing 20 mmol/L Tris/HCl, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L DTT, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), 1% Nonidet P-40 and 1% Triton X. Protein extracts were obtained by centrifugation of the lysate. The protein extract (25 lg) and positive controls of PPARc1 protein from Jurkat whole cell lysate (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were separated on 10% non-gradient acryl amide gel using sodium dodecyl acryl amide gel electrophoresis, then transferred to nitrocellulose membranes. Rabbit immunoglobulin G (IgG) antibodies against PPARc1 and a-smooth muscle actin (both Santa Cruz Biotechnology) were reacted (both at 1:1000 dilution), followed by peroxidase-linked protein A (Amersham Life Science, Buckinghamshire, UK). Immunoreactive bands were visualized by Western blotting detection electrochemiluminescence (ECL) reagents (Amersham) with the use of XOmatic AR film (Eastman-Kodak, Rochester, NY, USA).
Cellular contraction experiment
Cellular contraction experiment was carried out by the method previously described [26] . Briefly, rat mesangial cells were incubated in DMEM-F12 with 10% FBS and 10% Nu-serum containing either 5 or 20 mmol/L glucose in the presence and absence of appropriate concentrations of pioglitazone, troglitazone, indomethacin, acetyl salicylic acid, and 15dPGJ2 and PD98059 up to 5 days. The medium was changed every day. Effects of angiotensin II on the tonus of cells were examined by measuring the surface area of the cells. The cellular surface area was measured using cells cultured on 6-well plates. The cells were preincubated in DMEM-F12 with 5 mmol/L glucose containing 10% FBS and 10% Nu-serum for 1 hour at 37
• C in 95% air 5% CO 2 gas mixture. Cells cultured on 6-well plates were incubated in 20 mmol/L Tris/HEPES (pH 7.4) buffer containing (in mmol/L) glucose 5, NaCl 145, KCl 5, MgSO 4 2.5, and CaCl 2 1 in the presence of 10 −7 mol/L angiotensin II after washing three times with the same buffer. The cells were recorded by a light-microscope equipped with a digital camera (Nikon, Tokyo, Japan) for 30 minutes. Serial changes in the surface area were calculated using NIH image software (written by Wayne Rasband).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was prepared from rat mesangial cells cultured in the conditioned media using Isogen (Wako Junyaku, Osaka, Japan). To amplify the PPARc1 and GAPDH cDNA fragments, PCR primers for PPARc1 and GAPDH were synthesized as follows: forward primer sequences (5 -CCTCTCTCTGATGGATGACC-3 ) and (5 -TGAACGGGAAGCT CACTGG-3 ), and reverse • C, 30 seconds at 54
• C, and 30 seconds at 72
• C for PPARc1, and 19 cycles of 30 seconds at 94
• C, 30 seconds at 58
• C for GAPDH, using a thermal cycler (model 9600, Perkin Elmer-Cetus, Foster City, CA, USA). Each 8 lL of both PCR products were mixed with a loading buffer and then were electrophoresed in a 2% agarose gel. To confirm linearity of RT-PCR products of PPARc1 and GAPDH, 0.5, 1, 2, 3 lg of the stocked total RNA from mesangial cells cultured in 5 mmol/L glucose were used.
Antisense DNA for PPARc1
Antisense DNA and sense DNA for PPARc1 were synthesized as follows: antisense DNA sequences (5 -TGTCAACCATGGTAA-3 ) and sense DNA sequences (5 -TTACCATGGT TGACA-3 ), respectively. One lmol/L and 0.5 lmol/L of each antisense and sense DNA in OPTI-MEM (Sigma) were prepared after treatment with lipofectin for 15 minutes at room temperature. Rat mesangial cells on 60-mm plate and 6-well plate were washed 3 times with OPTI-MEM, and then were incubated in OPTI-MEM containing 0.5 and 1.0 lmol/L of either antisense DNA or sense DNA for 6 hours, respectively. The cells were washed 3 times with DMEM-F12, and then were incubated in DMEM-F12 containing 5 mmol/L glucose and 20% FBS for 48 hours. The cells on 60-mm plates were harvested to examine a-smooth muscle actin and PPARc1. The cells on 6-well plates were used for the cellular contraction study.
Other determinations
To determine cell viability, confluent mesangial cells on 96-well plate cultured in the media with different concentrations of pioglitazone for 5 days were used. The viability was quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-difenyltetrazolium bromide (MTT) assay purchased from Promega. Densitometric analyses were conducted using NIH image program.
Statistical analysis
Data were expressed as mean ± SEM. Differences between groups were examined for statistical significance using analysis of variance (ANOVA) and paired and unpaired Welch's t test (two-tailed). A P value less than 0.01 denoted the presence of a statistically significant difference.
RESULTS
Expression of PPARc 1 and of a-smooth muscle actin
The effect of TNFa and activation of PKC on PPARc1 protein is shown in Figure 1 . TNFa suppressed the PPARc1 protein after 24 hours. The PPARc1 protein did not change 1day after activation of PKC (data not shown); however, the protein decreased significantly after 2 days. The decreased PPARc1 protein by both TNFa (Fig. 5) .
Effect of angiotensin II and high glucose on cellular contraction
Representative photomicrographs of changes in surface area of mesangial cells in response to angiotensin II are shown in Figure 6 . Angiotensin II decreased surface area of mesangial cells in a dose-dependent manner. Angiotensin II more than 10 −8 mol/L significantly reduced the area (Fig. 7A) . The contractile response of the cells in 20 mmol/L glucose to angiotensin II did not differ from that in 5 mmol/L glucose until 3 days of incubation, and then decreased significantly after 5 days compared to those in 5 mmol/L glucose and in 20 mmol/L glucose after 1 and 3 days incubation (Fig. 7B) . The effects of 15dPGJ2, indomethacin, PD98059, and acetyl salicylic acid on the reduced contractile response 15dPGJ2, indomethacin, and PD98059 normalized the reduced contractile response in 20 mmol/L glucose to the response in 5 mmol/L glucose, respectively. However, acetyl salicylic acid (10 −4 mol/L) had no effect on the reduced contractile response in 20 mmol/L glucose (Fig. 9) .
Effect of antisense DNA for PPARc1 on PPARc1 protein, a-smooth muscle actin, and contractile response Both 0.5 and 1.0 lmol/L of antisense DNA significantly suppressed PPARc1 protein and increased a-smooth muscle actin, compared with those in DMEM-F12 with 0.5 and 1.0 lmol/L of sense DNA (Fig. 10A  and B) . Angiotensin II induced cellular contraction, and a significant 35% decrease of surface area in 5 mmol/L glucose alone was observed (Fig. 10C) . Antisense DNA suppressed completely the contractile function of mesangial cells. In the presence of sense DNA of 0.5 lmol/L and 1.0 lmol/L, angiotensin II significantly decreased the surface area and the degrees of the decrease were 29% and 23%, respectively. The degree of the decrease of surface area in 1.0 lmol/L sense DNA was significantly less compared with that in 5 mmol/L glucose alone.
DISCUSSION
In the regulation of PPARc, tumor necrosis factor-a (TNF-a) has been reported as an important factor to suppress PPARc at both protein and mRNA level in preadipocytes [27] [28] [29] [30] . Low levels of PPARc1 mRNA and protein have been reported in human macrophage cultured in high glucose [31] . We demonstrated that high glucose as well as TNF-a and PKC activation decreased PPARcl at both the protein and mRNA levels in rat mesangial cells. The suppression of PPARcl by these factors was normalized by the inhibition of MAPK. These results indicate MAPK activation down-regulates PPARcl expression at the transcriptional level. The activation of MAPK by TNFa and the suppression of PPARc action by MAPK have been reported in macrophage [32, 33] . In high glucose environments, activation of the DAG-PKC-ERK pathway has been reported to occur in rat mesangial cells [34] . The mechanism of the suppression of PPARcl under the high glucose condition seems to be explained by the activation of DAG-PKC-ERK pathway. The high glucose-induced PKC activation has been reported to occur after 3 days in rat aortic smooth muscle cells [35] , which may explain the delay in suppressing PPARcl protein under the high glucose condition. We also demonstrated pioglitazone induced PPARcl at both protein and mRNA levels. The induction of PPARcl at mRNA and protein levels by troglitazone [36] and the prevention of TNF-a-induced suppression in PPARcl mRNA by troglitazone, pioglitazone, and 15d-PGJ2 [28, 37] have been also reported. We reported that troglitazone normalized the increased cellular redox potential in rat mesangial cells in high glucose [38] . This effect of troglitazone may normalize PKC activity, since the increased cellular redox potential is reported to activate PKC activity [39] . Pioglitazone has been reported to normalize PKC activity in rat kidney [22] . The normalization of PKC activity may normalize MAPK activity in the DAG-PKC-ERK pathway. Indomethacin has been reported to inhibit MAPK [40] ; however, 15dPGJ2 and thiazolidinediones have been reported to activate MAPK recently [41, 42] . These reports indicate PPARc ligands other than indomethacin directly promote PPARcl protein at the level of gene expression independent of MAPK activity.
We examined a-smooth muscle actin as a marker of phenotypes of mesangial cells. a-Smooth muscle actin is not present in normal glomeruli and emerges in diseased glomeruli such as diabetic nephropathy [43] . PPARc ligands reversed the increased a-smooth muscle actin in 20 mmol/L glucose to the level in 5 mmol/L glucose. These results suggest that PPARc in rat mesangial cells also regulates phenotypes of the cells as reported in adipocytes [1, 29, 44] , and the phenotypic change by the suppression of PPARc1 under the high glucose condition is recovered to the phenotype under the normal glucose condition by PPARc ligands.
We also demonstrated the contraction of mesangial cells by measuring changes in the surface area of the cells, as reported previously [26] . The response of the cells to angiotensin II was similar to those described in previous studies [45] . Interestingly, the contractile response of the cells in 20 mmol/L glucose to angiotensin II decreased after 5 days incubation, which coincided with the decrease in PPARcl protein. Moreover, the decreased contractile response was attenuated by the normalization of PPARcl protein with PPARc ligands. These results indicate that the suppression of PPARc1 protein under the high glucose condition induces the contractile dysfunction of mesangial cells by changing the phenotype of the cells, since phenotypic change is important for cells to exhibit their functional properties, such as cellular contraction [7, 8, 46] .
A recent study raised PKC-mediated cytoskeletal dysfunction as a mechanism for the decreased contractile response in high glucose [47] . In this study, the decreased contractile response in high glucose was also recovered by the inhibition of MAPK with PD98059. Because MAPK positioned the downstream of PKC, activation of MAPK may be important for the decreased contractile response. However, PPARc ligands have been reported to activate MAPK as mentioned above [41, 42] . The suppression of PPARc1 protein by the activation of MAPK rather than the MAPK activation itself seems to be the cause of the high glucose-induced contractile dysfunction of the cells.
Moreover, we demonstrated the suppression of PPARc1 protein by the antisense DNA for PPARc1, that we made, induced an increase of a-smooth muscle actin and contractile dysfunction of mesangial cells in 5 mmol/L glucose. These results indicate that PPARc1 acts as a regulator of phenotype of mesangial cells and that the decrease of PPARc1 action by the suppression of its protein level induces de-differentiation of the cells, of which contractile function is decreased simultaneously.
The concentration of pioglitazone, which attenuates the high glucose-induced contractile dysfunction, is similar to the serum concentrations in diabetic patients treated with the same drug. Isshiki et al reported that pioglitazone recovered the glomerular hyper filtration, which is observed in the early stage of diabetic nephropathy, without affecting the sustained high blood glucose level in diabetic rats [22] . Normalization of PPARc1 protein by its ligands under the high glucose condition may contribute the beneficial effect on glomerular filtration by keeping the cellular phenotypes with normal contractile function.
We demonstrated the higher concentrations of pioglitazone more than 10 −5 mol/L decreased the contractility of rat mesangial cells in this study. Similar to pioglitazone, the high concentration of troglitazone (2.5 × 10 −6 mol/L) decreased the contractility of the cells, and lower concentration of the drug (2.5 × 10 −7 mol/L) prevented the reduced contractile response to in 20 mmol/L glucose (data not shown). The cell viability did not change at the concentration of pioglitazone up to 10 −5 mol/L; however, it significantly decreased at 10 −4 mol/L of the drug. Guan et al reported the similar effect of troglitazone on mesangial cells, and 2 × 10 −5 mol/L of troglitazone decreased the cell viability, while 1 × 10 −5 mol/L of troglitazone did not [48] . Pioglitazone and troglitazone have been reported to act as calcium channel blockers in smooth muscle cells, and those concentration were reported 3.0 × l0 −6 mol/L and 4.5 × l0 −5 mol/L, respectively [49, 50] . Recently, pioglitazone and troglitazone more than 10 −5 mol/L were also reported to suppress angiotensin II receptor at the transcriptional level [51] . These effects of pioglitazone on cell viability, calcium channel, and angiotensin II receptor may explain the suppression of the angiotensin II-induced cellular contraction at the higher concentration of the drug. The role of prostaglandin E2 on the reduced contractile response of mesangial cells in high glucose has been reported, since prostaglandin E2 decreases mesangial cell tonicity, and an increased production of prostaglandin E2 by mesangial cells in high glucose has also been reported [52, 53] . The concentrations of indomethacin and acetyl salicylic acid used in our study were sufficiently high to suppress prostaglandin synthesis [54, 55] ; however, only indomethacin as a PPARc ligand could attenuate the reduced contractile response. These data suggest that the reduced contractile response of cultured mesangial cells in high glucose is independent of prostaglandin E2.
CONCLUSION
We demonstrate that PPARc ligands attenuated the decreased contractile response of mesangial cells under the high glucose condition with the recovery of PPARcl protein and phenotypes of the cells.
